NOVARTIS AG
About NOVARTIS AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $284.6B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $284.6B
- Dividend yield
- 3.2%
- Shares outstanding
- 1.9B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 7, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 12% below its 52-week high.
- Pays a dividend yielding about 3.2% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NOVARTIS AG.
Write a review
News about NOVARTIS AG
News & sentiment via Polygon.io
